drugset

drugset / Trial / NCT00809510

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

NCT00809510 ↗

Phase 2 Terminated 63 enrolled Abbott

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with mild-to-moderate Alzheimer's disease.

Timeline

Start: 2009-01
Primary completion: 2009-06
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pozanicline	Small molecule	20 mg	—

Indications